Faes Farma (FAE) Q3 2025 earnings summary

Executive summary

• Total revenues increased by 15.5% year-over-year, reaching €454.0M, driven by growth across all business areas and successful M&A activity.

• Pharma revenues rose 13%, with LATAM (+16%) and Licences (+17%) as main growth drivers.

• Adjusted EBITDA grew 3% excluding M&A and extraordinary costs, while net profit declined 7.6% year-over-year.

• Strategic acquisitions of Laboratorio Edol (June) and SIFI S.P.A. (September) completed, strengthening the portfolio.

• New Strategic Plan 2025-2030 launched, and the Global Executive Team is now complete.

Financial highlights

• Income reached €454.0M (+15.5% year-over-year); pharma revenues €399.5M (+13.4%).

• Adjusted EBITDA was €112.8M (+3.0%), while reported EBITDA was €106.5M (-2.7%).

• Net profit was €73.6M, down 7.6% from the previous year.

• Gross margin improved to €300.4M (+11.2%).

• Ordinary income from sales grew 16.2% year-over-year.

Outlook and guidance

• Income for 2025 is guided to grow 8–10%, with 9M 2025 already at +15.5%.

• EBITDA for 2025 is guided at -6% to -9%, with 9M 2025 at -2.7%.

• Adjusted EBITDA for 2025 is guided at +3% to +5%, matching the 9M 2025 result of +3.0%.